Literature DB >> 12368952

Granulocyte colony-stimulating factor alone at 12 microg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients.

J Sevilla1, M González-Vicent, L Madero, F García-Sánchez, M A Díaz.   

Abstract

In children, the optimal mobilization schedule for harvesting peripheral blood progenitor cells (PBPC) is an issue of continuous research. We have studied a schedule based on high and daily divided doses of G-CSF (12 microg/kg body weight twice daily) for 4 days for PBPC priming. Toxicity related to G-CSF was observed in 13 patients (23%), mainly mild bone pain and myalgia. The median CD34(+)cell number collected was 4.4 (0.4-35 x 10(6)/kg body weight), with 46 patients achieving 2 x 10(6)/kg body weight (83.6%) after a single large volume leukapheresis. In conclusion, this mobilization schedule allows safe and efficient collection of the minimum target CD34(+) cell dose in most pediatric patients by only one procedure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368952     DOI: 10.1038/sj.bmt.1703662

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

Authors:  Antonio Pérez-Martínez; Alvaro Lassaletta; Marta González-Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

Authors:  Antonio Pérez-Martínez; Victor Quintero; Marta González Vicent; Julián Sevilla; Miguel Angel Díaz; Luis Madero
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 3.  Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.

Authors:  Saeed Mohammadi; Ashraf Malek Mohammadi; Mohsen Nikbakht; Amir Hossein Norooznezhad; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.